Clovis Oncology Announces CO-1686 Clinical Data Accepted as Oral Presentation at 2014 European Lung Cancer Conference

  Clovis Oncology Announces CO-1686 Clinical Data Accepted as Oral
  Presentation at 2014 European Lung Cancer Conference

JPMorgan Healthcare Conference 2014

Business Wire

BOULDER, Colo. -- December 23, 2013

Clovis Oncology (NASDAQ:CLVS) announced today that an abstract discussing the
findings of the ongoing Phase I portion of the Phase I/II clinical study of
CO-1686 has been accepted for Proffered Paper (Oral) presentation during the
4^th European Lung Cancer Conference (ELCC). CO-1686 is the Company’s novel,
oral, targeted covalent (irreversible) inhibitor of mutant forms of the
epidermal growth factor receptor (EGFR) for the treatment of non-small cell
lung cancer (NSCLC) in patients with initial activating EGFR mutations as well
as the dominant resistance mutation T790M. The conference takes place March
26-29, 2014 in Geneva, Switzerland.

This oral presentation will be the next update of clinical data from the Phase
I/II study of CO-1686. The Company intends to describe its clinical
development plan for CO-1686 at the JP Morgan Healthcare Conference in
mid-January and at the Clovis Oncology R&D Day for Investors and Analysts to
be held on January 27.

The abstract accepted for Proffered Paper (Oral) presentation is titled
“First-in-Human Evaluation of CO-1686, an Irreversible, Highly Selective
Tyrosine Kinase Inhibitor of Mutations of EGFR (Activating and T790M).” Data
contained in the ELCC abstract, which will be published in mid-March, was
current as of the submission deadline of December 9, 2013. Data to be
presented in the oral session will include more current data from the trial.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring,
developing and commercializing innovative anti-cancer agents in the U.S.,
Europe and additional international markets. Clovis Oncology targets
development programs at specific subsets of cancer populations, and
simultaneously develops diagnostic tools that direct a compound in development
to the population that is most likely to benefit from its use. Clovis Oncology
is headquartered in Boulder, Colorado.

To the extent that statements contained in this press release are not
descriptions of historical facts regarding Clovis Oncology, they are
forward-looking statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Such forward-looking statements
involve substantial risks and uncertainties that could cause our clinical
development programs, future results, performance or achievements to differ
significantly from those expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
uncertainties inherent in the initiation of future clinical trials,
availability of data from ongoing clinical trials, expectations for regulatory
approvals, and other matters that could affect the availability or commercial
potential of our drug candidates. Clovis Oncology undertakes no obligation to
update or revise any forward-looking statements. For a further description of
the risks and uncertainties that could cause actual results to differ from
those expressed in these forward-looking statements, as well as risks relating
to the business of the company in general, see Clovis Oncology’s Annual Report
on Form 10-K for the year ended December31, 2012 and its other reports filed
with the Securities and Exchange Commission.

Contact:

Clovis Oncology
Anna Sussman, 303-625-5022
asussman@clovisoncology.com
or
Breanna Burkart, 303-625-5023
bburkart@clovisoncology.com
 
Press spacebar to pause and continue. Press esc to stop.